Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting

November 10, 2022

https://www.globenewswire.com/news-release/2022/11/10/2553372/0/en/Medicenna-Presents-Updated-Clinical-Data-from-Dose-Escalation-Portion-of-Phase-1-2-ABILITY-Study-of-MDNA11-at-the-SITC-Annual-Meeting.html

– MDNA11’s selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation

Read more at globenewswire.com

Related news for (MDNA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.